stay updated

Khondrion is collaborating globally on its way to market

In July 2018 Khondrion was awarded €2.3M funding from the highly competitive EU Horizon 2020 SME instrument program to progress clinical development...

Khondrion features in new video from Catalyze-Group®

Khondrion granted Orphan Drug Designation for KH176 for the treatment of MIDD from European Commission

Khondrion granted Orphan Drug Designation for KH176 for the treatment of maternally inherited diabetes and deafness (MIDD) from European Commission...

Scientific publication in Cell Death & Disease

Results from collaborative preclinical research effort investigating Leigh disease patient cells published in Cell Death and Disease NIJMEGEN, the...

Publication of the KHENERGY study results

KHENERGY study provides first data on safety and efficacy of KH176 in patients with mitochondrial disease. Results from phase IIa study of innovative reduction-oxidation modulator published in Clinical Pharmacology and Therapeutics.

Khondrion awarded H2020 SME Instrument grant

Khondrion receives €2.3M funding from EU Horizon 2020 SME instrument phase 2 program.

Patient Perspective: A conversation with Elja van der Veer – Former IMP Chair

A coffee with the Scientific Advisory Board: Prof. Dr. Michelangelo Mancuso

How did you cross paths with Khondrion? I heard about Khondrion from International Mito-Patients, the global network of patient organisations, and...

Patient Perspective: A conversation with Sam’s mother

When did Sam first start experiencing symptoms and how long did it take for him to be diagnosed? Sam was first diagnosed with mitochondrial disease...

A coffee with the Scientific Advisory Board: Prof. Dr. Marni Falk

How did you cross paths with Khondrion? I have crossed paths with Jan Smeitink, Khondrion’s CEO and Founder, multiple times at various international...

Patient Perspective: A conversation with Paulien

When did you first start experiencing mitochondrial disease symptoms and how long did it take to get your diagnosis? I had a very happy and...

A coffee with the Scientific Advisory Board: Sir Prof. Dr. Emeritus Doug Turnbull, Chairman

How did you cross paths with Khondrion? I heard about Khondrion from international colleagues and was made aware that this company was focused on...